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COMMUNICATION ABOUT GENETIC EDITING 
CRISPR, BETWEEN OPTIMISM AND FALSE EXPECTATIONS
LLuís MontoLiu
Communication is essential in all areas of society, but communication in science is inescapable. 
Communicating means sharing, showing, teaching, and transferring knowledge about discoveries, 
observations, and findings both to colleagues and to society in general. That is why good 
communication must always accompany good science. CRISPR genetic editing tools allow us to 
modify, at will, the genome of any living organism, including our own species. In this text I review the 
different relevant communicative events in the short but intense life of these «molecular scissors», 
so called for their ability to cut the DNA molecule effectively and with precision.
Keywords:	CRISPR,	expectations,	interpretation,	uncertainty,	science	communication.
■■ THE	ORIGINS
Reading the explosion of texts about CRISPR 
(clustered regularly interspaced short palindromic 
repeats) genetic editing tools published over the last 
four or five years, one might think that they did not 
exist before 2012 and that they appeared suddenly, as 
if by chance. However, such coincidences are rare in 
science.
If we condense the history of genetic editing tools 
into the last five years, an important communication 
problem is revealed. We can look for different origins, 
but genetic editing – that is, the 
precise and specific modification 
of genetic sequences at the 
will of researchers – started in 
1985 with Oliver Smithies. He 
was the theorist of homologous 
recombination and an expert on 
how to exchange one, essentially 
identical, DNA sequence with 
another, and in so doing also 
removing any other sequence attached to the first; he 
saw that cutting the DNA sequence that he wanted 
to integrate into the corresponding homologous gene 
(in the genome sequence that shared the same letters 
as the donor molecule) very significantly increased 
the probability of correct insertion (Smithies, Gregg, 
Boggs, Koralewski, & Kucherlapati, 1985). Smithies 
was one of the three researchers who received the 
Nobel Prize in Medicine in 2007 for describing the 
method to inactivate specific genes in mice using 
pluripotent embryonic stem cells. These cells are 
erroneously called «mother» cells in Spanish, Catalan, 
and Galician, but the term has been successful in 
communication and even Spanish scientists use it 
regularly.
Years later French researchers from the Pasteur 
Institute used Smithies’ observation with the 
genome itself and discovered some enzymes called 
meganucleases, which can sever the genome at a 
precise spot in a unique way. Then, after 2001, zinc-
finger nucleases (ZFNs) were 
discovered and these leapt onto 
the scene in the media in 2009 
when they were first used to 
direct the specific inactivation 
of murine genes. Two years 
later, other enzymes, called 
transcription activator-like 
effector nucleases (TALENs), 
would be discovered in nature. 
These use pathogenic microorganisms from plants 
to revert the metabolism of the infected cells to 
their advantage. TALENs had their moment of glory 
until 2013, when the CRISPR tools were first used 
in genetic editing experiments with mammalian 
cells, specifically human cells (Fernández, Josa, 
& Montoliu, 2017). Thus, this is the story so far; 
therefore, the assumption that the field of genetic 
editing started with CRISPR is a misrepresentation. 
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Often, relatively few people are interested in the 
communication of scientific advances: generally, only 
those who work specifically in the field in which the 
findings are made. It is amazing to think how such 
relevant advances in genetic editing went virtually 
unnoticed by the general public for nearly 30 years. 
■■ CRISPR
What happened with CRISPRs? We learned about 
them in 2013, because of their spectacular and 
unexpected applications, which were both surprising 
and frightening, but they had been there for over 
25 years. Why did communication about them fail? 
Why did they not receive the space and interest they 
deserved sooner? Again, this is a case of specialised 
basic knowledge, of discoveries we fail to read from 
a different angle until we were shown their surprising 
and life-changing applications. 
In 1987, Japanese microbiologists discovered 
a repetitive DNA sequence while researching a 
chromosome fragment from Escherichia coli, 
bacteria which live in our intestines. They reported 
this strange finding but did not consider it important. 
Other Dutch microbiologists also found repetitive 
blocks of DNA sequences in different bacteria, 
Mycobacterium, responsible for tuberculosis and 
which, in evolutionary terms, are very different from 
E. coli. They decided to use these repeats in the 
genome to classify different isolates from the bacteria 
with different numbers of repeats. 
At the beginning of the nineties, for his PhD work, 
Francisco Juan Martínez Mojica (Francis Mojica) 
carried out experiments with microorganisms called 
Archaea, which live in extreme environments such 
as the Santa Pola salt marshes (Alicante, Spain). 
Archaea are prokaryotes (single cell microorganisms 
without a nucleus) like bacteria, but they are very 
different to them. Mojica also found repeats like 
those reported by Japanese and Dutch colleagues in 
Escherichia and Mycobacterium in Archaea. He also 
realised that, if three such disparate microorganisms 
so evolutionarily separated from each other shared 
these repetitive sequences, they might be useful 
and fulfil some function so that evolution would 

























rest of his professional career 
to understanding them. This 
decision put CRISPR (a name 
coined by Mojica in 2001 for 
these sequence repeats) on the 
path to becoming one of the most 
transformative tools in biology. 
Meanwhile, the general public 
and researchers not associated 
with CRISPR were unaware that 
a new revolution was brewing 
and that it would explode twelve years later. 
In 2003, Mojica had his great eureka moment. 
Reviewing unique segments between repeats in 
the DNA sequence (called «spacers» until then) 
he found similarities with the genome sequence of 
bacteriophages, viruses that infect bacteria. Even 
more importantly, he noticed that the bacteria 
carrying fragments of the genome of certain viruses 
were resistant (immune!) to infection by those viruses. 
In other words: he had just discovered an immune 
system in bacteria, an adaptive one that can learn 
and which was based on genetics, i.e., transmitted 
from bacteria to offspring bacteria. He confirmed 
this observation in other bacteria and then wrote 
and submitted a paper to the best scientific journals. 
However, they rejected his observations. Another 
serious communication problem and another great 
failure of the publication system. Three years went 
by with the paper bouncing from journal to journal, 
from rejection to rejection, until in 2005 he ended 
up publishing his data in a worthy but lesser journal, 
far from the spotlight and the most prominent covers 
(Mojica, Díez-Villaseñor, García-Martínez, & Soria, 
2005). Trying to communicate his incredible results 
almost cost Mojica his career and, when they were 
published, they were again widely ignored by the 
scientific community and society. It was just another 
paper published in one of many journals. 
Two years later, in 2007, French researchers carried 
out the experiment Mojica had been unable to: they 
transferred segments of sequences similar to virus 
genomes between different bacteria and in so, also 
transferred resistance to them. This experimentally 
verified Mojica’s initial observation. However, this 
publication would still not be enough to popularise 
the possibilities of genetic editing. 
In 2012 we had already accumulated a lot of 
knowledge about CRISPR’s systems because of their 
discovery in Archaea by Mojica and the description 
of elements constituting a bacterial defence system by 
the French team more than twenty years before. Then, 
two research teams suggested 
that the same CRISPR system 
used by bacteria to defend 
themselves from viruses could 
be used to modify the DNA 
sequence of any organism at 
will, whether plant or animal – 
or even human. A Lithuanian 
researcher, Virginijus Siksnys, 
was probably the first to notice 
this new application of the 
elements constituting the 
CRISPR system. He collected his observations and 
sent them to a journal that would end up delaying 
their publication (Gasiunas, Barrangou, Horvath, & 
Siksnys, 2012). 
Meanwhile, a collaboration between Jennifer 
Doudna and Emmanuelle Charpentier brought about 
by circumstance (they were working together to 
co-direct a postdoctoral researcher, but had worked 
independently until then and have not worked together 
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Siksnys. But, although they submitted after Siksnys 
they were able to use their privileged position to 
publish their paper in a prestigious journal in record 
time, just a couple months before Siksnys (Jinek et al., 
2012). This communication strategy placed the two 
researchers in the hall of fame and condemned the 
Lithuanian microbiologist to ostracism. Very few now 
remember him: yet another major communication 
problem.
Naturally, the institution where the two researchers 
worked at the time decided to keep their industrial 
rights over the use of CRISPR genetic editing 
tools, made entirely in the laboratory with bacteria, 
before publishing their observations. Thus, Berkeley 
University registered a patent 
application. However, their paper 
published in Science in August 
2012 did not prove that these 
CRISPR tools can be used to edit 
the genes of mammal cells – of 
human cells. It only proposed 
doing so. 
Several months later, Feng 
Zhang entered the scene. He 
was a researcher at the Broad 
Institute at Boston MIT who, 
in January 2013, proved for the 
first time that bacteria CRISPR tools could indeed be 
used as genetic editors in human cells (Cong et al., 
2013). His work coincided with the work of another 
researcher, George Church, also from Boston, who 
published his findings in the same issue of the journal 
Science (Mali et al., 2013). The Broad Institute, of 
course, also protected their researchers’ breakthrough 
and applied for the corresponding patent in late 
2012, months after Doudna and Charpentier filed for 
theirs. At that time, an extraordinary event occurred 
which irreversibly marked the subsequent history 
of CRISPR. Broad chose to use a riskier fast patent-
evaluation system that leaves no opportunity for 
corrections and has a significantly higher monetary 
cost. This coincided with a substantial change in the 
US Patent Office: they stopped granting patents to 
«the first to file an idea» and started giving them to 
«the first to prove its use». Doudna and Charpentier 
registered their patent before Zhang, but he was the 
first to prove that the CRISPR tools could be used for 
genetic editing in mammals. 
The Patent Office granted the patent to the Broad 
Institute in 2014. Berkeley University filed a lawsuit 
for patent interference, because they believed that 
Zhang had copied the idea, or at least, his experiments 
to prove the use of CRISPR in human cells had been 
based on their published experiments. Zhang and the 
Broad Institute defended themselves indicating that 
they had followed a parallel path almost at the same 
time as Doudna and Charpentier’s. Finally, in early 
2017, a US court rejected Berkeley’s interference 
lawsuit and confirmed that the Broad Institute was 
the owner of the patent1. This dispute became more 
complicated due to a review of the matter written by 
Eric Lader, director of the Broad Institute, who openly 
sided with Feng Zhang, his centre’s researcher, and 
blurred the role played by Doudna and Charpentier 
(Lander, 2016). The two researchers responded to his 
article in other media (Vence, 2016). 
Once again, the communication of results, the 
manner and timing of their 
transmission, the role of the 
narrator, and the communication 
channels used had relevant 
consequences for the entire 
process.
■■ CRISPR	COMMUNICATION
In 2013, the effectiveness of 
CRISPR in editing human or 
mouse cells was not only proven 
1  On 10 September 2018, the US Court of Appeals for the Federal Circuit 
finally awarded the pivotal CRISPR patent to the Broad Institute.
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for the first time, these tools were also 
used in pioneering work to create 
mutant mice and zebrafish. However, all 
these breakthroughs and applications 
collected together many basic scientific 
findings made in the eighties by 
microbiologists, biochemists, and 
molecular biologists whose previous 
work had facilitated the spread of this 
new technology around the world 
(Mojica & Montoliu, 2016). 
CRISPR tools have been used 
since 2013 in almost every field, 
from biology and biomedicine to 
biotechnology. At the beginning 
of 2016, three independent but related papers were 
published precisely in this field, proposing a novel 
administration method for CRISPR tools in model 
mice for a serious degenerative disease, Duchenne 
muscular dystrophy (Nelson et al., 2016). This work 
communicated, for the first time, that it was possible 
to restore the mutated gene causing a congenital 
disease in a significant number 
of cells of the affected organ 
– muscle fibres in this case – 
and this opened the possibility 
of using CRISPR as a somatic 
cell gene therapy tool to correct 
the mutation in affected cells. 
Undoubtedly the communication 
of this work has generated 
enormous expectations among 
the millions of patients around 
the world affected by a congenital disease. However, 
going from preclinical experiments with laboratory 
animals to clinical trials with patients is a step that 
requires extreme caution. We still cannot control 
the process of mutated gene correction well enough. 
The accuracy of CRISPR tools does not translate to 
the systems of cell repair that restore the DNA cut. 
These repair systems tend to generate a lot of genetic 
variability: many different types of DNA molecules 
among which the desired correct sequence can 
usually be found, albeit among many other sequences. 
This uncertainty, i.e., the genetic indeterminacy in 
correcting mutations in specific genes, has been 
confirmed in any genetic editing experiments in 
animals, whether in mice (Seruggia, Fernández, 
Cantero, Pelczar, & Montoliu, 2015) or human 
embryos (Liang et al., 2015). 
Very recent experiments seem to suggest that 
mosaicism (the coexistence of two or more cell 
populations with a different genetic composition in 
the same individual) can be controlled 
in human embryos. However, the 
pioneering work describing the 
genetic correction of the mutation in 
a gene associated with a congenital 
cardiomyopathy by using CRISPR (Ma 
et al., 2017) has already been met with 
a response from several laboratories 
suggesting alternative, less optimistic, 
explanations for this apparent removal 
of genetic uncertainty. The 
genetic correction system itself 
might mean that the researchers 
were unable to analyse mutations 
in the same way they had 
initially done, making them believe that the gene 
mutation was corrected when in reality, they were 
simply unable to detect the mutated gene (Egli et al., 
2017). Once again, the communication of potential 
advantages and solutions to a genetic problem might 
need to be revised, considering new results and new 
interpretations of previous results.
Additionally, CRISPR tools 
may cut DNA in sequences that 
are similar (rather than identical) 
to the ones that were initially 
planned, although this possibility 
has decreased as more specific 
guides using more powerful 
bioinformatics software have 
been designed. In fact, cuts at 
other points in the genome are 
very rare, or non-existent, in 
animal experiments (Seruggia et al., 2015). That is 
why another publication, in mid-2017 by American 
researchers, was so surprising. It described the 
existence of thousands of unexpected mutations in 
mice after a genetic editing experiment using CRISPR 
(Schaefer et al., 2017). This paper sparked great 
international controversy because it put a stop on all 
therapeutic hopes for CRISPR: who would want to 
use a therapeutic strategy associated with thousands 
of unexpected and uncontrolled mutations? 
This new communication problem even affected 
the stock value of publicly traded companies that 
work with genetic editing, whose shares plummeted 
after such negative results. However, the findings 
were not true; just a few days later, evidence and 
alternative explanations started to pile up proving 
that the mice used by the authors were different to 
those initially used in the genetic editing experiment 
to analyse the DNA sequences (Iyer et al., 2018). 
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manifested, and which this publication attributed 
to specificity problems derived from the use of 
CRISPR tools, had a much simpler explanation: the 
wrong genetic information had been used. It came 
from mice that were similar, but not identical, to 
the ones used in the initial experiment. In this case, 
social communication tools – social networks and 
blogs – were essential to quickly countering the 
apparently negative results reported in the paper with 
an alternative explanation. In a few weeks, we went 
from initial shock to a degree of embarrassment 
for the researchers involved, whose rookie mistake 
of comparing two different mouse lineages could 
have completely deposed the CRISPR tools from 
their privileged position in the treatment of genetic 
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Social networks and open science (thanks to 
articles published on blogs) were also essential to 
uncovering incorrect information in results published 
in May 2016 by a Chinese research team, who had 
announced that they had discovered new genetic 
editing tools – apparently much better than CRISPR. 
But the new tool, called NgAgo, seemed to work only 
in the laboratory that described it. In just two months, 
the first reviews appeared on different blogs, and soon 
after, researchers from around the world verified that 
the published results were not reproducible (Khin, 
Lowe, Jensen, & Burgio, 2017). Finally, in August 
2017, the journal responded to the general outcry by 
retracting the publication. 
China was not only burdened by frauds like NgAgo, 
it was also responsible for pioneering experiments 
using CRISPR in human embryos (Liang et al., 
2015), which explored the limits of the technique 
for correcting certain mutations. They noted – as in 
the rest of species tested – the uncertainty of results 
and phenomena such as genetic mosaicism and the 
possibility of altering other genome sequences, similar 
to those of the targets. Moreover, initially through 
press releases with partially published results, we 
have also learned about China’s world leadership 
in the race to use CRISPR tools to treat patients, by 
editing the genes of lymphocytes taken from the 
blood of cancer patients (Su et al., 2016). However, the 
first patient treated in vivo with genetic editing tools 
(although with ZFN, not CRISPR) was a Californian 
man, as part of a clinical trial approved in the USA 
and whose results were released to the public in 2017. 
In this paper I have related how communication 
topics have strongly impacted the development, 
knowledge, and application of the new CRISPR 
genetic editing tools. Similarly, I have also 
discussed the most controversial communicative 
aspects, especially the communication of apparently 
discouraging results, which have appeared on several 
occasions in the short history of genetic editing. 
But, similarly, this has favoured the publication 
of thousands of immediate responses by other 
researchers, who, using every communication channel 
within their reach, have managed to counter the 
pessimism or false hopes from such results until they 
can be properly analysed and adequately understood 
by other researchers and by society in general. 
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